PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosisZhe Wang(Xijing Hospital)Journal for ImmunoTherapy of CancerJune 1, 202310.1136/jitc-2023-006890Cited by 80SaveCiteExport RISWatch citationsRelated PapersDevelopment of Oral, Potent, and Selective CK1α Degraders for AML Therapy|JACS Au|2024|16